Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors

Capmatinib is a highly specific, potent and selective MET inhibitor. This was an open‐label, multicenter, dose‐escalation, phase I study conducted in Japanese patients with advanced solid tumors (not selected based on their MET status). The primary objective was to determine the maximum tolerated do...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Esaki, Taito, Hirai, Fumihiko, Makiyama, Akitaka, Seto, Takashi, Bando, Hideaki, Naito, Yoichi, Yoh, Kiyotaka, Ishihara, Kae, Kakizume, Tomoyuki, Natsume, Kazuto, Myers, Andrea, Doi, Toshihiko
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6447844/
https://ncbi.nlm.nih.gov/pubmed/30724423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13956
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge